Tanios Bekaii-Saab, MD, on the Past Year in Gastrointestinal Cancer Research

Video

The medical oncologist at the Mayo Clinic in Phoenix, spoke about the progress seen in gastrointestinal cancer research in 2020, as well as what improvements he hopes will occur in 2021.

Though this year brought many challenges, including navigating the coronavirus disease 2019 (COVID-19) pandemic, advancements in gastrointestinal cancer research still persisted.

In April, during the height of the COVID-19 pandemic, the FDA approved pemigatinib (Pemazyre) for advanced cholangiocarcinoma – a first for this patient population. Just a month later, the FDA also approved atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy. Moreover, the FDA is still reviewing a slew of agents for the treatment of gastrointestinal cancer.

In an interview with CancerNetwork®, Tanios Bekaii-Saab,MD, a medical oncologist at the Mayo Clinic in Phoenix, Arizona, discussed the advancements made in gastrointestinal cancer in 2020, as well as what improvements he hopes will occur in 2021.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Recent Videos
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Prolonging systemic therapy in patients with gastric or gastroesophageal junction cancers may offer better outcomes than radiation therapy.
Advances in perioperative targeted therapies may enable organ preservation and significantly enhance outcomes for patients with gastric cancers.
Related Content